ID: ALA5277295

Max Phase: Preclinical

Molecular Formula: C10H5ClF3NO3

Molecular Weight: 279.60

Associated Items:

Representations

Canonical SMILES:  O=[N+]([O-])C1=Cc2cccc(Cl)c2OC1C(F)(F)F

Standard InChI:  InChI=1S/C10H5ClF3NO3/c11-6-3-1-2-5-4-7(15(16)17)9(10(12,13)14)18-8(5)6/h1-4,9H

Standard InChI Key:  AZKZZLPMBCGDIM-UHFFFAOYSA-N

Associated Targets(Human)

Pyrimidinergic receptor P2Y6 717 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

P2Y purinoceptor 6 14 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 279.60Molecular Weight (Monoisotopic): 278.9910AlogP: 3.28#Rotatable Bonds: 1
Polar Surface Area: 52.37Molecular Species: HBA: 3HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 3.14CX LogD: 3.14
Aromatic Rings: 1Heavy Atoms: 18QED Weighted: 0.59Np Likeness Score: -0.59

References

1. Jung YH, Shah Q, Lewicki SA, Pramanik A, Gopinatth V, Pelletier J, Sévigny J, Iqbal J, Jacobson KA..  (2022)  Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists.,  75  [PMID:36089113] [10.1016/j.bmcl.2022.128981]

Source